Tyme Technologies Inc (NASDAQ:TYME) CEO Steve Hoffman sold 51,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $1.21, for a total transaction of $61,710.00. Following the sale, the chief executive officer now directly owns 26,390,449 shares of the company’s stock, valued at $31,932,443.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Steve Hoffman also recently made the following trade(s):

  • On Thursday, July 16th, Steve Hoffman sold 51,299 shares of Tyme Technologies stock. The shares were sold at an average price of $1.26, for a total transaction of $64,636.74.

Shares of NASDAQ:TYME opened at $1.22 on Friday. The company has a market cap of $153.19 million, a PE ratio of -6.78 and a beta of 0.97. Tyme Technologies Inc has a 52 week low of $0.86 and a 52 week high of $2.04. The firm has a 50 day simple moving average of $1.30 and a 200 day simple moving average of $1.33.

Tyme Technologies (NASDAQ:TYME) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.03. As a group, sell-side analysts predict that Tyme Technologies Inc will post -0.28 EPS for the current year.

TYME has been the subject of several recent research reports. Zacks Investment Research raised shares of Tyme Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, July 21st. HC Wainwright reissued a “buy” rating and set a $9.50 target price on shares of Tyme Technologies in a research note on Thursday, May 21st. Finally, Canaccord Genuity reissued a “buy” rating on shares of Tyme Technologies in a research note on Monday, June 29th.

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new stake in shares of Tyme Technologies in the 4th quarter valued at approximately $25,000. Citigroup Inc. increased its stake in Tyme Technologies by 72.2% in the 4th quarter. Citigroup Inc. now owns 23,556 shares of the company’s stock valued at $33,000 after buying an additional 9,873 shares during the period. Advisor Group Holdings Inc. acquired a new position in Tyme Technologies in the 1st quarter valued at approximately $28,000. Ladenburg Thalmann Financial Services Inc. increased its stake in Tyme Technologies by 12,625.0% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 25,450 shares of the company’s stock valued at $36,000 after buying an additional 25,250 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in Tyme Technologies by 31.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 42,232 shares of the company’s stock valued at $59,000 after buying an additional 10,124 shares during the period. Institutional investors and hedge funds own 11.89% of the company’s stock.

About Tyme Technologies

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Recommended Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.